How GLP-1s Lower Your Risk of Heart Disease

You probably know that GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have transformed how we treat obesity. But large clinical trials show these medications also reduce the risk of heart attack, stroke, and cardiovascular death — benefits that weight loss alone can’t fully explain.

Heart disease is driven by a range of issues, including insulin resistance, chronic inflammation, and blood vessel dysfunction. GLP-1s appear to address these issues directly, improving how the body responds to insulin, dialing down bodywide inflammation, and helping blood vessels function more normally.

You don’t have to have obesity for these processes to take hold. Even people in a “normal” weight range tend to develop some degree of insulin resistance, inflammation, and blood vessel dysfunction in midlife as metabolism shifts with age. Because these changes cause no symptoms and rarely show up on standard bloodwork, they often go undetected until real damage has been done. That’s the window where interventions like GLP-1s may matter most.

How GLP-1s Offer Real-World Heart Protection

The evidence that GLP1-s reduce the risk of heart attack and stroke comes from large cardiovascular outcomes trials designed to measure what researchers call MACE, major adverse cardiovascular events. These studies are the gold standard for heart protection claims.

In trials focused on people with type 2 diabetes, a population already at elevated heart risk, GLP-1s consistently reduced serious cardiovascular events by 12–26% depending on the drug and population, with strong results for stroke prevention. When researchers pooled data across seven of these trials, the overall reduction held at 13%.¹

Newer evidence shows these benefits extend beyond people with diabetes. A landmark trial of more than 17,600 overweight and obese patients with cardiovascular disease (but not diabetes), found that semaglutide reduced their risk of serious cardiovascular events by 20%. In an analysis of similar patients, the risk of heart attack was reduced by 28%.² 

We don’t yet have long-term trials on the newest GLP medications — like tirzepatide, which targets two metabolic pathways instead of one — but early data suggest potentially even bigger reductions in both serious cardiac events and overall mortality. Researchers are also seeing improvements in blood pressure, inflammation, cholesterol, and liver fat, each of which is independently linked to heart risk.³

These findings move GLP-1s out of the “weight-loss drug” category and into the category of proven cardiovascular risk-reduction tools. The question is no longer whether they protect the heart. It’s how.

GLP-1s Reduce Inflammation

Traditional cardiology frames heart disease as a plumbing problem — arteries slowly clog until fully blocked — which is why a standard lipid panel focuses almost entirely on cholesterol. But what actually triggers a heart attack is less about how much plaque has built up and more about whether that plaque is stable. And the factor that most determines stability is inflammation.

Think of heart disease as a fire. Cholesterol is the fuel circulating in the bloodstream, and by itself it isn’t necessarily dangerous. Inflammation is what lights the match. When the inflammatory burden is high — from insulin resistance, dyslipidemia (high LDL/triglycerides), high blood pressure, and liver stress — it drives cholesterol particles into the artery lining and triggers the plaque buildup that can eventually rupture and cut off blood flow to the heart. This is why two people with similar cholesterol numbers can have very different cardiac risk profiles. 

Inflammation also changes what cholesterol does. ApoB, the protein that packages cholesterol into particles for transport, acts like a fleet of delivery trucks. In an inflamed environment, those trucks don’t pass through cleanly; they get pulled into the artery wall. The more ApoB particles in circulation, and the smaller they are, the deeper they penetrate — and the more fuel they deliver to an already active fire.

Taking GLP-1s has been shown to reduce markers of inflammation. In clinical trials, semaglutide reduced CRP, a protein the liver releases when the body is in a state of chronic inflammatory stress, by 40–50%.⁴ The medications appear to be working directly on the inflammatory pathways themselves.⁵

Blood vessel lining and plaque stability

When chronic inflammation is reduced, artery linings become less permeable to cholesterol, less hospitable to plaque formation, and better able to keep existing plaques stable and contained. That’s important because stabilized plaque is far less likely to rupture and cause a heart attack.⁶

Measurable blood pressure reductions

When inflammation is high, it causes blood vessels to stiffen and makes the heart work harder to pump blood effectively. As inflammation recedes, blood vessels regain their natural flexibility, helping blood flow more smoothly and easily and allowing blood pressure to drop.

Clinical research shows that GLP-1s lower systolic blood pressure (the top number in a blood pressure reading; it’s a key measure of arterial tension) significantly and consistently, and even mild improvements in blood pressure translate to meaningful outcomes. The systolic reduction from semaglutide contributed to a 20% reduction in major cardiovascular events.⁷

GLP-1s Improve Insulin Sensitivity 

Insulin resistance is one of the most damaging drivers of heart disease. In a healthy system, muscles pull glucose from the blood for energy. But when cells stop responding to insulin efficiently, the liver steps in to manage the overflow, converting excess blood sugar into triglycerides and releasing them into the bloodstream.

Those triglycerides don’t just circulate harmlessly — they ultimately end up depositing fat directly into muscle tissue, impairing the insulin receptors that are supposed to be clearing glucose from the blood. The result is a vicious cycle: more triglycerides, more insulin resistance, more cardiovascular damage.

GLP-1s appear to run that cycle in reverse. They improve insulin signaling within weeks, even in people without diabetes, which reduces the liver’s overproduction of triglycerides and allows muscle tissue to recover insulin receptor function.⁸ The GLP-1 tirzepatide has been shown to reduce triglycerides by 13–20%.⁹ Fewer triglycerides in circulation also means fewer ApoB particles, which research now identifies as the most accurate measure of cardiovascular risk from dyslipidemia (imbalance of fats in the blood).¹⁰

GLP-1s also reduce visceral fat, the metabolically active fat stored around internal organs that feeds this cycle in the first place.¹¹ Because visceral fat and insulin resistance reinforce each other, reducing one helps interrupt the other, ultimately lowering the disease process that increases cardiovascular risk.

GLP-1s Improve Liver-Driven Heart Risk

Think of the liver as the body’s primary refinery. It’s responsible for “packaging” your cholesterol and determining whether it remains stable or becomes the dangerous, unstable particles that lead to heart disease. 

When this refinery is stressed or “clogged” with fat, it loses the ability to maintain quality control, releasing high-risk particles that trigger a cascade of inflammation and metabolic instability. Research shows that fatty liver disease is associated with a 64% increased risk of heart attack or stroke.¹² 

GLP-1s reduce liver fat by about 5–8%, a reduction that sounds modest but represents a major relative drop in stored fat.^{13 14} Beyond lowering fat accumulation in the liver, GLP-1s also improve liver-driven heart risk by decreasing inflammation and reducing levels of enzymes that release artery-damaging particles. ¹⁵

Who May Benefit Most From GLP-1s for Heart Health

By addressing the root drivers of heart disease — including inflammation, insulin resistance, and liver stress — GLP-1s can be a powerful tool for anyone with significant cardiovascular risk, even if their weight is in the “normal” BMI range. Here’s who might benefit most:

• People with insulin resistance or metabolic syndrome who have chronically elevated insulin levels that increase the production of artery-damaging cholesterol particles
• People with fatty liver disease and dyslipidemia (abnormal amount of fats in the blood) who need to lower inflammation and stress on the liver, bringing down high triglycerides and inhibiting production of artery-damaging cholesterol particles
• People whose blood work shows elevated levels of these biomarkers:
  • ApoB: The total count of all plaque forming particles in the blood. Levels above 90 mg/dL increase the risk for heart disease, regardless of what your total cholesterol number is.  
  • hs-CRP: A measure of systemic inflammation in the body. ACC/AHA guidelines flag levels above 2.0 mg/L as higher cardiovascular risk; at Hone, we’re targeting levels above 1.0 mg/L.
  • Lp(a): A genetically determined, highly inflammatory type of cholesterol. Levels above 50 mg/dL increase heart attack risk. GLP-1s may not influence Lp(a), but elevated levels indicate the need for intervention.  

GLP-1 medications are FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater alongside at least one weight-related condition, such as high blood pressure, Type 2 diabetes, or high cholesterol. However, these diagnostic parameters neglect how beneficial GLP-1s can be for heart health and longevity for people with a normal BMI who have early warning signs of heart disease. 

How GLP-1s Fit Into Hone’s Heart Health Strategy

At Hone, GLP-1s aren’t prescribed based on BMI alone. They’re triggered by specific metabolic, inflammatory, and liver stress patterns in the blood work. GLP-1s are used as part of a broader health strategy that includes lifestyle changes and other medications as needed:

• Metabolic-first lifestyle support: Hone recommends a protein-forward whole foods diet and limiting ultra-processed foods to help stabilize blood sugar and prevent the insulin spikes that can damage arteries. Resistance training is also essential because it helps preserve muscle, the body’s most metabolically active tissue. By maintaining muscle, you improve your body’s ability to process glucose, which reduces the metabolic load on your liver and protects your heart.
  
• Targeted lipid management: When markers like ApoB or Lp(a) test consistently high, a Hone doctor might recommend pairing GLP-1s with other cholesterol-lowering medications, such as statins. This two-pronged approach reduces the total amount of cholesterol and improves the liver’s ability to package it safely to leave your body.
  
• Systemic inflammation control: By monitoring markers of blood vessel inflammation, your doctor can adjust your protocol to keep the heat low. This might include pairing GLP-1s with targeted supplements like Omega-3 fatty acids or adding a statin to prevent the oxidation and rupture of existing plaque.

When “hidden” risks like insulin resistance and liver stress are identified early, tools like GLP-1s can help stabilize your system and protect your heart health for the long haul.

Real Science, Real Results

Get expert insights on fueling your body, supporting metabolism, and living longer—delivered to your inbox every Monday.

"*" indicates required fields

Name*

Email*

Subscribe to*

Hone In: Men’s health, performance, and longevity

Hone Your Life: Women’s health, hormones, and well-being

Join The Hone Newsletter

About the author

Dr. Abid Husain is a Consulting Physician and Scientific Advisor for Hone Health. As a triple-board-certified cardiologist and integrative medicine physician, Dr. Husain combines his background in traditional cardiology with functional medicine to offer a unique, multi-faceted modality of care.